7.82
price down icon3.10%   -0.25
after-market After Hours: 7.81 -0.01 -0.13%
loading
Amneal Pharmaceuticals Inc stock is traded at $7.82, with a volume of 1.88M. It is down -3.10% in the last 24 hours and down -3.34% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$8.07
Open:
$7.95
24h Volume:
1.88M
Relative Volume:
1.11
Market Cap:
$2.45B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-11.49
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-2.25%
1M Performance:
-3.34%
6M Performance:
-5.33%
1Y Performance:
+6.68%
1-Day Range:
Value
$7.79
$8.07
1-Week Range:
Value
$7.79
$8.235
52-Week Range:
Value
$6.50
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
Name
Amneal Pharmaceuticals Inc
Name
Phone
908-947-3120
Name
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
Employee
5,210
Name
Twitter
@amnealpharma
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
7.82 2.53B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
145.79 66.25B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.72 42.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.43 43.30B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.45 19.30B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
128.23 13.53B 2.41B 305.80M 492.20M 2.95

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-25 Initiated Goldman Buy
Feb-24-25 Upgrade JP Morgan Neutral → Overweight
Sep-06-24 Upgrade JP Morgan Underweight → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Mar-08-21 Upgrade Goldman Sell → Buy
Dec-14-20 Upgrade Barclays Equal Weight → Overweight
Dec-14-20 Upgrade Guggenheim Neutral → Buy
Jul-27-20 Initiated Goldman Sell
May-12-20 Upgrade Guggenheim Sell → Neutral
Dec-12-19 Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19 Downgrade JP Morgan Neutral → Underweight
Nov-07-19 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19 Upgrade SVB Leerink Mkt Perform → Outperform
Jul-11-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-08-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-11-19 Initiated Barclays Equal Weight
May-21-19 Upgrade Raymond James Mkt Perform → Strong Buy
Mar-20-19 Initiated SunTrust Buy
Mar-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
Dec-14-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-16-18 Downgrade SunTrust Buy → Hold
Aug-13-18 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-23-18 Initiated Morgan Stanley Overweight
Jun-22-18 Initiated B. Riley FBR, Inc. Buy
View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

pulisher
Jul 31, 2025

What makes Amneal Pharmaceuticals Inc. stock price move sharplyBreakout Stocks Tips For Beginners - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

What is Amneal Pharmaceuticals Inc. company’s growth strategyBreakout Stocks Strategy With Low Risk - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - Insider Monkey

Jul 31, 2025
pulisher
Jul 31, 2025

Amneal Launches GLP-1 Agonist Exenatide Injection - Specialty Pharmacy Continuum

Jul 31, 2025
pulisher
Jul 30, 2025

Teva Drops Inhaler Patent Infringement Lawsuit Against Amneal - Bloomberg Law News

Jul 30, 2025
pulisher
Jul 30, 2025

Is Amneal Pharmaceuticals Inc. a candidate for recovery playReversal Alert Based on RSI Indicator Confirmed - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Amneal Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayStock Market Watch With Alerts Shows Unusual Activity - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Teva, Amneal End Case Over Listing Inhaler IP In Orange Book - Law360

Jul 29, 2025
pulisher
Jul 29, 2025

Why Amneal Pharmaceuticals Inc. stock attracts strong analyst attentionAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com

Jul 29, 2025
pulisher
Jul 29, 2025

Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet - Zacks Investment Research

Jul 29, 2025
pulisher
Jul 29, 2025

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Q1 Earnings Highlights: Amneal, ANI, Amphastar, and ViatrisNews and Statistics - IndexBox

Jul 29, 2025
pulisher
Jul 29, 2025

Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 09:45:24 - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-28 20:38:28 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Amneal Pharmaceuticals Inc.Capitalize on momentum stocks early - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is Amneal Pharmaceuticals Inc. a growth stock or a value stockAchieve consistent profits with smart trading - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What institutional investors are buying Amneal Pharmaceuticals Inc. stockExceptional earning trajectories - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Amneal Pharmaceuticals Inc. generate profit in a changing economyUnlock high-yield investment opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Achieve rapid financial growth with expert picks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

How Amneal Pharmaceuticals Inc. stock performs during market volatilityFree Stock Selection with 300% Return - metal.it

Jul 26, 2025
pulisher
Jul 26, 2025

Truist Financial Sticks to Its Buy Rating for Amneal Pharmaceuticals (AMRX) - The Globe and Mail

Jul 26, 2025
pulisher
Jul 25, 2025

Amneal Pharmaceuticals Inc. Stock Analysis and ForecastMassive portfolio appreciation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Amneal Pharmaceuticals Inc. stock priceFree Investment Community - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Amneal Pharmaceuticals Prices $600M Senior Notes Offering - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $8 - 富途牛牛

Jul 25, 2025
pulisher
Jul 25, 2025

Is Amneal Pharmaceuticals Inc. a good long term investmentPowerful profit generation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan - Investing.com Nigeria

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Amneal Pharmaceuticals Inc. stockFree Investment Community - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan By Investing.com - Investing.com South Africa

Jul 24, 2025
pulisher
Jul 24, 2025

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S - simplywall.st

Jul 24, 2025
pulisher
Jul 22, 2025

Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire

Jul 22, 2025
pulisher
Jul 21, 2025

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal seeks to borrow $1.8 billion in new term loans, offers notes - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal seeks to borrow $1.8 billion in new term loans, offers notes By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal reports 3% revenue growth in Q2, advances deleveraging - Investing.com

Jul 21, 2025

Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.19
price down icon 0.90%
$13.68
price down icon 3.12%
$8.74
price down icon 2.89%
drug_manufacturers_specialty_generic RDY
$14.22
price up icon 0.85%
$274.70
price down icon 2.57%
$128.23
price down icon 6.24%
Cap:     |  Volume (24h):